Jennison Associates
AKBA icon

Jennison Associates’s Akebia Therapeutics AKBA Stock Holding History

Jennison Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,934
Closed -$502K – 622
2020
Q2 		$502K Buy
+36,934
New +$382K ﹤0.01% 594
2014
Q4 		– Sell
-179,232
Closed -$3.97M – 718
2014
Q3 		$3.97M Buy
179,232
+257
+0.1% +$5.9K ﹤0.01% 516
2014
Q2 		$4.97M Buy
+178,975
New +$4.31M ﹤0.01% 505

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jennison Associates's AKBA Position: Q3 2020 in Review

Jennison Associates sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 36,934 shares — an estimated $502K sold.

Jennison Associates first reported a position in AKBA in Q2 2014 and held it in 3 quarters. The position peaked at $4.97M in Q2 2014. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Jennison Associates reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Jennison Associates sold 36,934 Akebia Therapeutics shares in Q3 2020, an estimated $502K.
  • Jennison Associates first reported a position in Akebia Therapeutics in Q2 2014 and held it in 3 quarters.
  • Jennison Associates's Akebia Therapeutics position peaked at $4.97M in Q2 2014.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Jennison Associates's 13F filing for Q3 2020, filed 4 Nov 2020.